|Scientific and program committee 2017|
|Magnus Gisslén is professor of Infectious Diseases at the University of Gothenburg, Sweden. He shares his time between clinical work with HIV patients as head of the HIV unit at the Department of Infectious Diseases, Sahlgrenska University Hospital in Gothenburg, Sweden, and clinical HIV research, holding a research position at the Swedish Research Council. The main interest of his current research is HIV persistence and latent reservoirs, mainly focusing on the HIV infection of the central nervous system. He also serves as HIV consultant in 20 Infectious Disease Clinics around Sweden.|
|Nina Weis is associate professor and senior physician at Copenhagen University Hospital, Hvidovre, Denmark. She is Head of DANHEP, the Danish Database for Hepatitis B and C, with chronic viral hepatitis being the main topic of her research; both investigator initiated and in clinical trials of direct acting antiviral therapy of hepatitis C.|
|Anders Sönnerborg is professor of Infectious Diseases and Clinical Virology at Karolinska Institutet, Sweden. He shares his time between clinical work with HIV patients, responsibility for clinical molecular-virology diagnostics for HIV and hepatitis, and clinical/
translational research on HIV and hepatitis C virus. The main interest of his current research is HIV cure including persistence and latent reservoirs and consequences of microbial translocation/
immuneactivation as well as HIV infection in low-middle income countries.
|Ola Weiland has a present position as head of the Liver Disease Section of the Department of Medicine, Division of Infectious Diseases at the Karolinska Institute, Karolinska University Hospital site Huddinge, Stockholm, Sweden. He is also senior professor in Infectious Diseases at Karolinska Institutet at the Department. He has been Head Master for Medical Education within the Department until 2006. Professor Weiland has received his medical degree from Karolinska Institute in 1972 and achieved board certification as a Specialist in
Infectious Diseases in 1977. His research on hepatitis A, B and non-A, non-B virus gained him a PhD at the Karolinska Institute in 1981. Professor Weiland is a member of the European and American Association for Study of the Liver, the Infectious Disease Society of America, and the Swedish Societies for Medicine, Infectious Diseases, and Tropical Medicine. He is also president of the Society of the Scandinavian Journal of Infectious Diseases and is on the board of the Scandinavian Journal of Gastroenterology. He has published over 250 original
articles, in addition to 40 reviews or book chapters. His main research interests covers the mechanisms of action, immunological response to, clinical development, and evaluation of antiviral therapy for chronic hepatitis B and C.
|Soo Aleman, MD, PhD, assoc prof is working as hepatologist at department of Infectious Diseases and department of Gastroenterology and Hepatology at Karolinska University Hospital, Sweden. The main focus of her current research is to assess the risks and risk factors for hepatocellular cancer after hepatitis C treatment with sustained virological response in clinical cohort studies. She has also research collaborations about clinical and translational studies about hepatitis B/D/C nationally and internationally. She is currently the main investigator of a genomic study of hepatocellular carcinoma developed after hepatitis C cure in an international network from Europe, USA and Canada.|
|Anders Blaxhult is an associate professor at Karolinska Institute, Stockholm with an interest especially in epidemiology and treatment of HIV. He has also for many years worked as an HIV clinician and is currently senior consultant at Venhälsan, Södersjukhuset, an inner city clinic in Stockholm with 1300 HIV patients and a major STI clinic for men who have sex with men. He has also been involved in international HIV projects in different parts of the world.|
|Francesca Chiodi is Professor in Host-Parasite Interaction. She has been the supervisor of 25 PhD students. She is the author of more than 120 publications in the field of HIV virology and immunology. Her research is translational and focuses on characterizing the molecular mechanisms leading to declined function and number of B and T cells during HIV infection. Her group has conducted extensive functional and phenotypical studies on B and T cells in HIV infected patients and the impact of early ART on the biology of these cells.|
|An infectious disease doctor at Akershus University hospital in Ahus, Norway. Olav is also a professor at the Olso University. His research interests are HCV among addicts and treatment for HCV Genotype 3 infections.|
Anne Ma Dyrhol-Riise
|Specialist of infectious diseases and work as clinician and professor at the Dept. of Infectious Diseases, Oslo University Hospital and Institute for Clinical Medicine, University of Oslo where she is head of the “Chronic Infectious Diseases” research group. She is also professor at the Institute of Clinical Science, University of Bergen. She has background from basic and clinical HIV and tuberculosis research and has been project leader in international and national studies with focus on translational research on immune mechanisms, diagnostic and prognostic biomarkers and clinical trials with therapeutic vaccination.|
|Leo Flamholc is a specialist in infectious diseases and a senior consultant at the Department of Infectious Diseases Skane University Hospital in Malmo Sweden. He has been active in HIV care since the early days of the epidemic and has participated in numerous clinical trials within the HIV and hepatitis C area. He has also been involved in international projects and worked with HIV care in resource limited settings.|
|Martti Färkkilä is a professor of gastroenterology at Helsinki University and head of Clinic of Gastroenterology at Helsinki University Hospital (HUCH). His main interests are treatment of viral hepatitis, cholestatic liver diseases and inflammatory bowel disease. He has been responsible for the treatment guidelines for HCV and HBV at HUCH. He has supervised 12 PhD students and published almost 200 orginal papers.|
|Jan Gerstoft is professor of clinical virology at the University of Copenhagen, Denmark. He works at the department of infectious diseases at Rigshospitalet where he is heading the outpatient clinic that primarily takes care of HIV and hepatitis patients. His research has mainly been focused on HIV, since he described the first European AIDS patients in 1981. His research has involved clinical trials of antiviral agents, resistance and cohort studies of co-morbidities. The research has been published in more than 400 papers often in high impact journals.|
|Magnús Gottfreðsson is professor of Infectious Diseases at the School of Health Sciences at the University of Iceland. He is also chief, Department of Science at Landspitali University Hospital, Reykjavik. He divides his time between clinical teaching, research and administration. His diverse research interests include HIV clinical and epidemiologic research, studies on fungal infections and genetic determinants of host susceptibility to infectious diseases.|
|Have been working as an independent researcher and group leader at Karolinska Institutet since 2005, after completing her postdoctoral
training at Gladstone Institute of Virology and Immunology, University of California San Francisco, San Francisco, CA, USA. Dr Karlsson’s research group are using a translational approach with basic studies linking viral evolution and immunological patterns in clinical samples to understand the underlying mechanisms of HIV specific T cell function and pathogenesis. Specifically, they aim to unravel basic immunological and virological dynamics so that immunological approaches can be developed to restore T cell function and thereby provide a framework to rationally design a prophylactic or therapeutic vaccine.
|Magnus Lindh is professor in clinical virology at the University of Gothenburg and head of the virology section at Clinical Microbiology, Sahlgrenska University Hospital. His main research interest is molecular and clinical aspects on chronic hepatitis B virus infection.|
|Senior consultant at the Department of Infectious Diseases, Ullevål University Hospital, Oslo, Norway.|
|(MD 2002, Ph.D. 2009) A fellow in infectious diseases at Rigshospitalet in Copenhagen, Denmark. She has 4 years as Ph.D. and post.doc at
the HIV Drug Resistance Program at NCI-Frederick, Frederick, MD, USA, under the supervision of Dr. John Coffin. Her research centers on investigating evolution and population dynamics in HIV and HCV during different host/drug pressure.
|Dr Matti Ristola is Head of HIV Services at the Division of Infectious Diseases in the Helsinki University Central Hospital in Finland.
Dr Ristola received his MD from the University of Helsinki in 1979. He completed his PhD thesis on neutrophil immunology in 1991. He became a specialist in internal medicine in 1987 and in infectious diseases in 1993.
His research interests include clinical studies on antiretroviral therapy and HIV epidemiology among injecting drug users. He has also studied mycobacterial infections among HIV patients.
Veronica Svedhem Johansson
|Specialist in infectious diseases and senior consultant at the Infectious Disease Clinic, Karolinska University Hospital. Responsible for the National quality assurance registry InfCareHIV. Member of Prof Anders Sonnerborgs research grop, clinical unit, at the Department of Medicine, Huddinge, Karolinska Institut. The main current interests are Registry studies on InfCareHIV, Causes of death, Late HIV diagnosis, HIV-related stigma and quality of life.|
|Matti Sällberg, born in Stockholm in 1961, obtained both DDS and a PhD degrees from Karolinska institutet in 1992. Hed did a post doc from 1994-1996 at the Scripps Research Institute, La Jolla, San Diego. He returned to KI and became a full professor in 2000 at the division of clinical microbiology. In 2011 he became Head of Department of Laboratory Medicine, Karolinska Institute, a position which he still holdst. His research group has focused on the immune responses and pathogenesis of chronic viral hepatitis. He has putblished >150 scientific papers, supervised 26 PhD students, a number of post docs. A major scientific achievement was to take a in house developed DNA vaccine against chronic HCV to clinical testing in patients. The group has developed several unique mouse models.|
|Aylin Yilmaz is a specialist in infectious diseases and a senior consultant at the Department of Infectious Diseases at Sahlgrenska University Hospital, Gothenburg, Sweden. Her research mainly focuses on HIV-infection and the central nervous system.|